licensing agreement

Immunotech will acquire the rights to develop and commercialize 800TCR, T-Cure's autologous T-cell receptor therapy, for renal cell carcinoma.

Biond is also eligible to receive more than $1 billion in development, regulatory, and sales milestone payments, and tiered royalty payments.

Zai Lab paid $25 million upfront for rights to develop and commercialize TPX-0022 in mainland China, Hong Kong, Macau, and Taiwan.

The firm will garner exclusive rights to develop and commercialize ABI-009 in the Chinese territories and pay Aadi up to $271 million.

The company has acquired a SHP2 inhibitor and an ERK inhibitor through two worldwide licensing agreements and has begun testing the former in the clinic.

Zai Lab will pay Cullinan $20 million upfront to license the drug in Greater China and could pay up to $211 million in future milestones and royalties.

Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.

The Roche subsidiary will take over development of RLY-1971 and study it in combination with other drugs, such as its KRAS G12C inhibitor GDC-6036.

As part of the deal, Atara will receive $60 million upfront and be eligible for up to $610 million in milestone payments, as well as tiered royalties based on net sales.

Artios can receive $30 million in up-front and near-term payments, and up to $860 million per target if Merck KGaA exercises its exclusive development rights.